SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending as investors rally ahead of quarterly earnings, driven by optimism regarding the company's AI cloud infrastructure, large-scale backlog, and a new partnership with HPE for data center networking. While traders remain focused on the potential for a breakout and institutional short covering, some express caution over capital expenditure levels and the broader macroeconomic environment.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is receiving significant attention as traders debate the stock's potential for a turnaround, fueled by speculation regarding government support and the broader AI semiconductor sector. While some investors remain skeptical, pointing to execution risks and valuation concerns, many are optimistic about long-term growth prospects.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders debate potential market volatility driven by escalating geopolitical tensions between the U.S. and Iran, rising oil prices, and upcoming economic data releases, including PPI and CPI prints. Community sentiment remains polarized, with some traders anticipating an aggressive market rally while others highlight concerns over inflation, interest rate policies, and broader economic risks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as traders react to a breakout above the $1,000 level and sustained demand for memory chips supporting AI infrastructure. The community sentiment remains bullish on long-term prospects, with discussions focusing on the potential for continued upside heading into the upcoming earnings report, despite ongoing debates regarding technical resistance levels and broader geopolitical risks.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining attention due to its position as a key liquidity hub on the Base network and anticipation surrounding a cross-chain merger. Investors are expressing optimism about upcoming platform upgrades and institutional adoption, though discussions remain fragmented by speculative price targets and noise from smaller, unrelated assets.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as the stock experiences a strong rally, largely driven by its correlation to Bitcoin's price movement and bullish investor sentiment. Traders are debating the sustainability of this momentum, with some citing institutional buying and positive technical setups, while others caution against potential volatility and market manipulation.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as the company officially becomes a dual-primary listed entity on the Hong Kong Stock Exchange, a move designed to expand its investor base and increase liquidity. Traders are debating the long-term potential of the stock's AI initiatives versus near-term pressure from advertising revenue performance and macroeconomic headwinds.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as traders debate the company's potential in physical AI, robotics, and the automotive sector, with many investors pointing to QNX software and the upcoming Alloy Kore platform as catalysts for future growth. While some investors express frustration over recent stock volatility and management's communication regarding timelines, others maintain long-term conviction, citing increasing institutional ownership and the company's integration into major industry tech stacks.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community is debating the potential market impact of escalating geopolitical tensions between the U.S. and Iran, rising oil prices, and upcoming U.S. tariff measures against Canada. While some traders express bearish caution due to these inflationary pressures and expected volatility, others are focused on technical setups or are dismissing the risks as overblown.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently trending as investors debate the impact of broader market volatility, high interest rates, and cooling sentiment in the semiconductor sector. While some traders express frustration over recent price action and volatility, others remain focused on long-term growth driven by AI infrastructure deployments and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IRWD apraglutide works right? Like there’s no way it’s gonna be inferior to GATTEX?  Or a safety concern? Because if these guys blow it and they spent 1.1 bill on apraglutide they’re idiots.

StockTwits for iOS

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

 apraglutide works right? Like there’s no way it’s gonna be inferior to GATTEX?  Or a safety concern? Because if these guys blow it and they spent 1.1 bill on apraglutide they’re idiots.

Willie

@wtzou The CRL was about bye inconsistent dosing right?  Safety good.  Assume it works, had statistically proven or an NDA would be so sumb even these idiots wouldn’t have filed.  That said. The c suite is weak so who knows?

$IRWD There&#39;s no actual CRL on apraglutide, that&#39;s Zealand&#39;s glepaglutide from Dec &#39;24 people are mixing it up with. Ironwood pulled back mid rolling submission after its own PK reanalysis showed underdosing tied to a trial administration issue, and FDA then required a confirmatory Phase 3, so this was a strategic withdrawal pre completion, not a formal rejection. Efficacy hit statistical significance on the primary endpoint, apraglutide beat placebo -25.5% vs -12.5% (P=.001) at week 24, with a safety profile essentially identical to placebo. The GATTEX comparison is really about daily dosing vs. apraglutide&#39;s once weekly profile, not an efficacy gap. STARS2 (NCT07742735) is actively recruiting now under VectivBio AG, 24 weeks is a shorter design than Zealand&#39;s 52 week confirmatory comp, and if Fast Track ends up applying here it would compress the review side further, Real risk here is the enrollment timeline on a rare disease population, not a safety or efficacy failure.

StockTwits Web

Twits Ghost

 The CRL was about bye inconsistent dosing right?  Safety good.  Assume it works, had statistically proven or an NDA would be so sumb even these idiots wouldn’t have filed.  That said. The c suite is weak so who knows?

Raylin Jones

@wtzou what is the ph3 trail result is expected to come out ? Any clue

 what is the ph3 trail result is expected to come out ? Any clue

cert M

@cert Current Status of ApraglutideFDA Requirement: The FDA informed Ironwood Pharmaceuticals that a new confirmatory Phase 3 trial is necessary for short bowel syndrome with intestinal failure (SBS-IF) approval.  
 
 Trial Design Alignment: Ironwood Pharmaceuticals met with the FDA in late 2025 and finalized the design for this confirmatory Phase 3 STARS-2 trial.  
 
Trial Timeline: The company initiated the new confirmatory Phase 3 trial in the first half of 2026. Final results and subsequent regulatory submission timelines will depend on the progress of this ongoing trial.

 Current Status of ApraglutideFDA Requirement: The FDA informed Ironwood Pharmaceuticals that a new confirmatory Phase 3 trial is necessary for short bowel syndrome with intestinal failure (SBS-IF) approval.  
 
 Trial Design Alignment: Ironwood Pharmaceuticals met with the FDA in late 2025 and finalized the design for this confirmatory Phase 3 STARS-2 trial.  
 
Trial Timeline: The company initiated the new confirmatory Phase 3 trial in the first half of 2026. Final results and subsequent regulatory submission timelines will depend on the progress of this ongoing trial.

@cert Based on Ironwood Pharmaceuticals&#39; current timeline, the estimated progression looks as follows:  
 
Estimated Milestone TimelineTrial Initiation: June 2026 (The trial was officially initiated and is actively recruiting patients).  
 
Patient Enrollment Window: Typically, a rare disease global trial like this (targeting Short Bowel Syndrome with Intestinal Failure) requires 12 to 18 months to fully enroll all cohorts. This places full enrollment around mid-to-late 2027.  
 
Primary Treatment Period: Patients are evaluated over a 24-week period (approx. 6 months) measuring the relative change in weekly parenteral support volume.

 Based on Ironwood Pharmaceuticals' current timeline, the estimated progression looks as follows:  
 
Estimated Milestone TimelineTrial Initiation: June 2026 (The trial was officially initiated and is actively recruiting patients).  
 
Patient Enrollment Window: Typically, a rare disease global trial like this (targeting Short Bowel Syndrome with Intestinal Failure) requires 12 to 18 months to fully enroll all cohorts. This places full enrollment around mid-to-late 2027.  
 
Primary Treatment Period: Patients are evaluated over a 24-week period (approx. 6 months) measuring the relative change in weekly parenteral support volume.

@cert  So given IRWD history of taking their time to deliver trial results, we are probably looking at mid 2028 for P3 readout and late 2028 for FDA Approval and Apraglutide commercialization in mid 2029.  And minimal press releases / updates because the management are terrible at preserving shareholder value. Now if they change the CEO..... we could have much more communication and improvement in shareholder sentiment.

  So given IRWD history of taking their time to deliver trial results, we are probably looking at mid 2028 for P3 readout and late 2028 for FDA Approval and Apraglutide commercialization in mid 2029.  And minimal press releases / updates because the management are terrible at preserving shareholder value. Now if they change the CEO..... we could have much more communication and improvement in shareholder sentiment.